Associated Papers
Metabolism of the antipsychotic drug olanzapine by CYP3A43.
Zhao J et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2022
Ancestry-Adjusted Vitamin D Metabolite Concentrations in Association With Cytochrome P450 3A Polymorphisms.
Wilson RT et al.
American Journal of Epidemiology, 2018
Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study.
Siemes C et al.
Steroids, 2010
Review of studies on metabolic genes and cancer in populations of African descent.
Ragin CC et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2010
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clinical Pharmacokinetics, 2006
Analysis of restriction fragment length polymorphism of cytochrome P450 3A43 gene and evaluation of the incidence of CYP3A43*1B allele in europeoid residents of West Siberia.
Shchepotina EG et al.
Bulletin of Experimental Biology and Medicine, 2005
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.
Stone A et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2005
Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer.
Singh AS et al.
Nature Clinical Practice. Urology, 2005
First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: identification of a loss-of-function variant.
Cauffiez C et al.
Human Mutation, 2004
Sequence diversity and haplotype structure at the human CYP3A cluster.
Thompson EE et al.
The Pharmacogenomics Journal, 0